Gonorrhea is caused by the infection of the bacterium Neisseria gonorrhea, which usually affects the moist and warm areas of the body, such as the vagina, anus, urethra, throat, and eyes. It is classified as the second most common sexually transmitted disease (STD) as it has the potential to spread through unprotected sex or multiple sexual partners. Due to the high morbidity rate and imminent threat of gonorrhea being resistant to cephalosporin, it is necessary to understand the disease epidemiology of gonorrhea. As per the latest research cited in the Centers for Disease Control and Prevention’s 2016 report, the global prevalence of gonorrhea is 142.1 cases per 100,000 people. The occurrence is higher in women in comparison to men and is widely prevalent in regions such as North America, Latin America, Africa, and other developing nations of South Asia.
The World Health Organization has postulated a treatment guideline for gonorrhea in order to overcome the problem of microbial resistance, which consists of the use of antibiotics such as third-generation cephalosporins, doxycycline, azithromycin, gemifloxacin, etc. For effective diagnosis of gonorrhea, the cell culture standard test is considered the gold standard due to its inherent features such as high specificity, high sensitivity, and relatively low cost. The problems associated with the cell culture of Neisseria are the need to maintain bacterial viability during storage and transport, and approximately 24–72 hours are required before a preliminary culture test result is obtained. The nucleic acid amplification test (NAAT) has been approved by the USFDA for analyzing genital specimens only and has been beneficial in gaining positive results with very little genetic material, urine samples, and vaginal swabs. For analyzing extra-genital specimens, gonorrhea diagnosis is performed with serological tests, monoclonal antibody tests, flow cytometry, etc.
The gonorrhea diagnostics market is segmented on the following basis:
- Flow Cytometry
- Diagnostic Imaging
- Gel Microdroplets
- Monoclonal antibody tests
- Differential light scattering
Molecular diagnostic tests
- Swab Tests
- Nucleic Acid Amplification Tests (NAAT)
- North America
- United States
- United Kingdom
- Rest of Europe
- Rest of Asia Pacific
- rest of Latin America
Middle East and Africa
- Rest of the Middle East and Africa
Key players identified for the gonorrhea diagnostics market include:
Abbott Laboratories, Agilent Technologies, Beckman Coulter, Inc., Becton Dickinson & Company, bioMérieux, Inc., Cepheid, Inc., PerkinElmer, Inc., Pfizer, Inc., Roche Diagnostics, and Siemens AG
This report offers:
- The market assessment is done by furnishing the market size and compounded annual growth rate, considering 2017 as the base year and the period from 2018 to 2026 as the forecast period.
- For the geography and type segments, an attractive investment proposition is given, which helps diagnostic manufacturers contemplate useful financial decisions.
- The competitive landscape helps in determining the competitive milieu currently existing in the gonorrhea diagnostics market.
- The financial health of leading players is considered in the financial information segment, and a diverse range of diagnostic kits and types are covered in the product portfolio section. Recent news coverage keeps us informed regarding the latest strategic developments and their impact on the gonorrhea diagnostics market.